Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 307

1.

Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness.

Filippatou A, Shoemaker T, Esch M, Qutab M, Gonzalez-Caldito N, Prince JL, Mowry EM, Calabresi PA, Saidha S, Sotirchos ES.

Mult Scler. 2018 Dec 3:1352458518815597. doi: 10.1177/1352458518815597. [Epub ahead of print]

PMID:
30507269
2.

Alu insertion variants alter mRNA splicing.

Payer LM, Steranka JP, Ardeljan D, Walker J, Fitzgerald KC, Calabresi PA, Cooper TA, Burns KH.

Nucleic Acids Res. 2018 Nov 10. doi: 10.1093/nar/gky1086. [Epub ahead of print]

PMID:
30418605
3.

The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis.

Balcer LJ, Balk LJ, Brandt AU, Calabresi PA, Martinez-Lapiscina EH, Nolan RC, Paul F, Petzold A, Saidha S.

J Neuroophthalmol. 2018 Dec;38(4):494-501. doi: 10.1097/WNO.0000000000000732.

PMID:
30418332
4.

Microvascular blood flow velocities measured with a retinal function imager: inter-eye correlations in healthy controls and an exploration in multiple sclerosis.

Wang L, Kwakyi O, Nguyen J, Ogbuokiri E, Murphy O, Caldito NG, Balcer L, Frohman E, Frohman T, Calabresi PA, Saidha S.

Eye Vis (Lond). 2018 Nov 2;5:29. doi: 10.1186/s40662-018-0123-0. eCollection 2018.

5.

Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior.

Linville RM, DeStefano JG, Sklar MB, Xu Z, Farrell AM, Bogorad MI, Chu C, Walczak P, Cheng L, Mahairaki V, Whartenby KA, Calabresi PA, Searson PC.

Biomaterials. 2019 Jan;190-191:24-37. doi: 10.1016/j.biomaterials.2018.10.023. Epub 2018 Oct 25.

PMID:
30391800
6.

Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Caldito NG, Saidha S, Sotirchos ES, Dewey BE, Cowley NJ, Glaister J, Fitzgerald KC, Al-Louzi O, Nguyen J, Rothman A, Ogbuokiri E, Fioravante N, Feldman S, Kwakyi O, Risher H, Kimbrough D, Frohman TC, Frohman E, Balcer L, Crainiceanu C, Van Zijl PCM, Mowry EM, Reich DS, Oh J, Pham DL, Prince J, Calabresi PA.

Brain. 2018 Nov 1;141(11):3115-3129. doi: 10.1093/brain/awy245.

PMID:
30312381
7.

Emerging Applications of Optical Coherence Tomography Angiography (OCTA) in neurological research.

Wang L, Murphy O, Caldito NG, Calabresi PA, Saidha S.

Eye Vis (Lond). 2018 May 12;5:11. doi: 10.1186/s40662-018-0104-3. eCollection 2018. Review.

8.

Dice Overlap Measures for Objects of Unknown Number: Application to Lesion Segmentation.

Oguz I, Carass A, Pham DL, Roy S, Subbana N, Calabresi PA, Yushkevich PA, Shinohara RT, Prince JL.

Brainlesion (2017). 2018;10670:3-14. doi: 10.1007/978-3-319-75238-9_1. Epub 2018 Feb 17.

PMID:
29714358
9.

Joint Intensity Fusion Image Synthesis Applied to Multiple Sclerosis Lesion Segmentation.

Fleishman GM, Valcarcel A, Pham DL, Roy S, Calabresi PA, Yushkevich P, Shinohara RT, Oguz I.

Brainlesion (2017). 2018;10670:43-54. Epub 2018 Feb 17.

PMID:
29714357
10.

Visual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis.

Nguyen J, Rothman A, Fitzgerald K, Whetstone A, Syc-Mazurek S, Aquino J, Balcer LJ, Frohman EM, Frohman TC, Crainiceanu C, Beier M, Newsome SD, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Jul;43(7):941-948. doi: 10.1080/02713683.2018.1459730. Epub 2018 May 1.

PMID:
29634379
11.

Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity.

Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, Calabresi PA, Snyder SH.

Science. 2018 Apr 27;360(6387):449-453. doi: 10.1126/science.aan4665. Epub 2018 Mar 29.

12.

MIMoSA: An Automated Method for Intermodal Segmentation Analysis of Multiple Sclerosis Brain Lesions.

Valcarcel AM, Linn KA, Vandekar SN, Satterthwaite TD, Muschelli J, Calabresi PA, Pham DL, Martin ML, Shinohara RT.

J Neuroimaging. 2018 Jul;28(4):389-398. doi: 10.1111/jon.12506. Epub 2018 Mar 8.

PMID:
29516669
13.

Central vein sign in multiple sclerosis: Ready for front and center?

Miller AE, Calabresi PA.

Neurology. 2018 Apr 3;90(14):631-632. doi: 10.1212/WNL.0000000000005241. Epub 2018 Mar 7. No abstract available.

PMID:
29514945
14.

An Automated Statistical Technique for Counting Distinct Multiple Sclerosis Lesions.

Dworkin JD, Linn KA, Oguz I, Fleishman GM, Bakshi R, Nair G, Calabresi PA, Henry RG, Oh J, Papinutto N, Pelletier D, Rooney W, Stern W, Sicotte NL, Reich DS, Shinohara RT; North American Imaging in Multiple Sclerosis Cooperative.

AJNR Am J Neuroradiol. 2018 Apr;39(4):626-633. doi: 10.3174/ajnr.A5556. Epub 2018 Feb 22.

15.

Bryostatin-1 alleviates experimental multiple sclerosis.

Kornberg MD, Smith MD, Shirazi HA, Calabresi PA, Snyder SH, Kim PM.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2186-2191. doi: 10.1073/pnas.1719902115. Epub 2018 Feb 12.

16.

Optimal Intereye Difference Thresholds in Retinal Nerve Fiber Layer Thickness for Predicting a Unilateral Optic Nerve Lesion in Multiple Sclerosis.

Nolan RC, Galetta SL, Frohman TC, Frohman EM, Calabresi PA, Castrillo-Viguera C, Cadavid D, Balcer LJ.

J Neuroophthalmol. 2018 Dec;38(4):451-458. doi: 10.1097/WNO.0000000000000629.

PMID:
29384802
17.

Defining response profiles after alemtuzumab: Rare paradoxical disease exacerbation.

Wiendl H, Calabresi PA, Meuth SG.

Neurology. 2018 Feb 13;90(7):309-311. doi: 10.1212/WNL.0000000000004969. Epub 2018 Jan 19. No abstract available.

PMID:
29352097
18.

Multiple Sclerosis.

Reich DS, Lucchinetti CF, Calabresi PA.

N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. Review. No abstract available.

PMID:
29320652
19.

Advances in multiple sclerosis: from reduced relapses to remedies.

Calabresi PA.

Lancet Neurol. 2018 Jan;17(1):10-12. doi: 10.1016/S1474-4422(17)30417-9. Epub 2017 Dec 16. No abstract available.

PMID:
29262991
20.

Analysis of Agreement of Retinal-Layer Thickness Measures Derived from the Segmentation of Horizontal and Vertical Spectralis OCT Macular Scans.

Gonzalez Caldito N, Antony B, He Y, Lang A, Nguyen J, Rothman A, Ogbuokiri E, Avornu A, Balcer L, Frohman E, Frohman TC, Bhargava P, Prince J, Calabresi PA, Saidha S.

Curr Eye Res. 2018 Mar;43(3):415-423. doi: 10.1080/02713683.2017.1406526. Epub 2017 Dec 14.

PMID:
29240464
21.

Distinguishing among multiple sclerosis fallers, near-fallers and non-fallers.

Fritz NE, Eloyan A, Baynes M, Newsome SD, Calabresi PA, Zackowski KM.

Mult Scler Relat Disord. 2018 Jan;19:99-104. doi: 10.1016/j.msard.2017.11.019. Epub 2017 Nov 22.

PMID:
29182996
22.

Characteristics of morphologic macular abnormalities in neuroimmunology practice.

Al-Louzi O, Sotirchos ES, Vidal-Jordana A, Beh SC, Button J, Ying HS, Balcer LJ, Frohman EM, Saidha S, Calabresi PA, Newsome SD.

Mult Scler. 2017 Nov 1:1352458517741206. doi: 10.1177/1352458517741206. [Epub ahead of print]

PMID:
29125422
23.

Dimethyl fumarate treatment alters NK cell function in multiple sclerosis.

Smith MD, Calabresi PA, Bhargava P.

Eur J Immunol. 2018 Feb;48(2):380-383. doi: 10.1002/eji.201747277. Epub 2017 Dec 15.

PMID:
29108094
24.

The NAIMS cooperative pilot project: Design, implementation and future directions.

Oh J, Bakshi R, Calabresi PA, Crainiceanu C, Henry RG, Nair G, Papinutto N, Constable RT, Reich DS, Pelletier D, Rooney W, Schwartz D, Tagge I, Shinohara RT, Simon JH, Sicotte NL; NAIMS Cooperative Steering Committee.

Mult Scler. 2018 Nov;24(13):1770-1772. doi: 10.1177/1352458517739990. Epub 2017 Nov 6.

PMID:
29106329
25.

Intensity inhomogeneity correction of SD-OCT data using macular flatspace.

Lang A, Carass A, Jedynak BM, Solomon SD, Calabresi PA, Prince JL.

Med Image Anal. 2018 Jan;43:85-97. doi: 10.1016/j.media.2017.09.008. Epub 2017 Oct 12.

PMID:
29040910
26.

Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation.

Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM.

JCI Insight. 2017 Oct 5;2(19). pii: 95302. doi: 10.1172/jci.insight.95302. [Epub ahead of print]

27.

Lineage tracing reveals dynamic changes in oligodendrocyte precursor cells following cuprizone-induced demyelination.

Baxi EG, DeBruin J, Jin J, Strasburger HJ, Smith MD, Orthmann-Murphy JL, Schott JT, Fairchild AN, Bergles DE, Calabresi PA.

Glia. 2017 Dec;65(12):2087-2098. doi: 10.1002/glia.23229. Epub 2017 Sep 22.

28.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis.

Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL.

Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.

PMID:
28920886
29.

Thalamus segmentation using multi-modal feature classification: Validation and pilot study of an age-matched cohort.

Glaister J, Carass A, NessAiver T, Stough JV, Saidha S, Calabresi PA, Prince JL.

Neuroimage. 2017 Sep;158:430-440. doi: 10.1016/j.neuroimage.2017.06.047. Epub 2017 Jun 29.

30.

Volumetric Analysis from a Harmonized Multisite Brain MRI Study of a Single Subject with Multiple Sclerosis.

Shinohara RT, Oh J, Nair G, Calabresi PA, Davatzikos C, Doshi J, Henry RG, Kim G, Linn KA, Papinutto N, Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Stern W, Tummala S, Yousuf F, Zhu A, Sicotte NL, Bakshi R; NAIMS Cooperative.

AJNR Am J Neuroradiol. 2017 Aug;38(8):1501-1509. doi: 10.3174/ajnr.A5254. Epub 2017 Jun 22.

31.

Gradient nonlinearity effects on upper cervical spinal cord area measurement from 3D T1 -weighted brain MRI acquisitions.

Papinutto N, Bakshi R, Bischof A, Calabresi PA, Caverzasi E, Constable RT, Datta E, Kirkish G, Nair G, Oh J, Pelletier D, Pham DL, Reich DS, Rooney W, Roy S, Schwartz D, Shinohara RT, Sicotte NL, Stern WA, Tagge I, Tauhid S, Tummala S, Henry RG; North American Imaging in Multiple Sclerosis Cooperative(NAIMS).

Magn Reson Med. 2018 Mar;79(3):1595-1601. doi: 10.1002/mrm.26776. Epub 2017 Jun 15.

PMID:
28617996
32.

Longitudinal multiple sclerosis lesion segmentation data resource.

Carass A, Roy S, Jog A, Cuzzocreo JL, Magrath E, Gherman A, Button J, Nguyen J, Bazin PL, Calabresi PA, Crainiceanu CM, Ellingsen LM, Reich DS, Prince JL, Pham DL.

Data Brief. 2017 Apr 8;12:346-350. doi: 10.1016/j.dib.2017.04.004. eCollection 2017 Jun.

33.

Dimethyl fumarate alters B-cell memory and cytokine production in MS patients.

Smith MD, Martin KA, Calabresi PA, Bhargava P.

Ann Clin Transl Neurol. 2017 Apr 17;4(5):351-355. doi: 10.1002/acn3.411. eCollection 2017 May.

34.

Retrograde trans-synaptic visual pathway degeneration in multiple sclerosis: A case series.

Al-Louzi O, Button J, Newsome SD, Calabresi PA, Saidha S.

Mult Scler. 2017 Jun;23(7):1035-1039. doi: 10.1177/1352458516679035. Epub 2017 Apr 7.

35.

Quantitative measures of walking and strength provide insight into brain corticospinal tract pathology in multiple sclerosis.

Fritz NE, Keller J, Calabresi PA, Zackowski KM.

Neuroimage Clin. 2017 Feb 20;14:490-498. doi: 10.1016/j.nicl.2017.02.006. eCollection 2017.

36.

Neuropsychiatric syndromes of multiple sclerosis.

Murphy R, O'Donoghue S, Counihan T, McDonald C, Calabresi PA, Ahmed MA, Kaplin A, Hallahan B.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):697-708. doi: 10.1136/jnnp-2016-315367. Epub 2017 Mar 11. Review.

PMID:
28285265
37.

Ultra-high-field (7.0 Tesla and above) MRI is now necessary to make the next step forward in understanding MS pathophysiology - Commentary.

Calabresi PA, van Zijl PC.

Mult Scler. 2017 Mar;23(3):376-377. doi: 10.1177/1352458516684560. Epub 2016 Dec 16. No abstract available.

38.
39.

From neurofilament research to multiple sclerosis clinical practice: Where do we stand?

Bodini B, Calabresi PA.

Neurology. 2017 Feb 28;88(9):816-817. doi: 10.1212/WNL.0000000000003676. Epub 2017 Feb 1. No abstract available.

PMID:
28148634
40.

Retinal Architecture and Melanopsin-Mediated Pupillary Response Characteristics: A Putative Pathophysiologic Signature for the Retino-Hypothalamic Tract in Multiple Sclerosis.

Meltzer E, Sguigna PV, Subei A, Beh S, Kildebeck E, Conger D, Conger A, Lucero M, Frohman BS, Frohman AN, Saidha S, Galetta S, Calabresi PA, Rennaker R, Frohman TC, Kardon RH, Balcer LJ, Frohman EM.

JAMA Neurol. 2017 May 1;74(5):574-582. doi: 10.1001/jamaneurol.2016.5131.

41.

Longitudinal multiple sclerosis lesion segmentation: Resource and challenge.

Carass A, Roy S, Jog A, Cuzzocreo JL, Magrath E, Gherman A, Button J, Nguyen J, Prados F, Sudre CH, Jorge Cardoso M, Cawley N, Ciccarelli O, Wheeler-Kingshott CAM, Ourselin S, Catanese L, Deshpande H, Maurel P, Commowick O, Barillot C, Tomas-Fernandez X, Warfield SK, Vaidya S, Chunduru A, Muthuganapathy R, Krishnamurthi G, Jesson A, Arbel T, Maier O, Handels H, Iheme LO, Unay D, Jain S, Sima DM, Smeets D, Ghafoorian M, Platel B, Birenbaum A, Greenspan H, Bazin PL, Calabresi PA, Crainiceanu CM, Ellingsen LM, Reich DS, Prince JL, Pham DL.

Neuroimage. 2017 Mar 1;148:77-102. doi: 10.1016/j.neuroimage.2016.12.064. Epub 2017 Jan 11.

42.

Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.

Button J, Al-Louzi O, Lang A, Bhargava P, Newsome SD, Frohman T, Balcer LJ, Frohman EM, Prince J, Calabresi PA, Saidha S.

Neurology. 2017 Feb 7;88(6):525-532. doi: 10.1212/WNL.0000000000003582. Epub 2017 Jan 11.

43.

CNS-targeted autoimmunity leads to increased influenza mortality in mice.

Glenn JD, Smith MD, Xue P, Chan-Li Y, Collins S, Calabresi PA, Horton MR, Whartenby KA.

J Exp Med. 2017 Feb;214(2):297-307. doi: 10.1084/jem.20160517. Epub 2017 Jan 5.

44.

Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.

Gordon-Lipkin E, Calabresi PA.

J Neuroimmunol. 2017 Mar 15;304:93-96. doi: 10.1016/j.jneuroim.2016.12.003. Epub 2016 Dec 14. Review.

PMID:
28038893
45.

B-Cell Depletion - A Frontier in Monoclonal Antibodies for Multiple Sclerosis.

Calabresi PA.

N Engl J Med. 2017 Jan 19;376(3):280-282. doi: 10.1056/NEJMe1614717. Epub 2016 Dec 21. No abstract available.

PMID:
28001486
46.

Therapeutic Application of Monoclonal Antibodies in Multiple Sclerosis.

Orthmann-Murphy JL, Calabresi PA.

Clin Pharmacol Ther. 2017 Jan;101(1):52-64. doi: 10.1002/cpt.547. Epub 2016 Nov 24. Review.

PMID:
27804128
47.

Pain, cognition and quality of life associate with structural measures of brain volume loss in multiple sclerosis.

Fritz NE, Roy S, Keller J, Prince J, Calabresi PA, Zackowski KM.

NeuroRehabilitation. 2016 Oct 14;39(4):535-544.

48.

The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson.

Kildebeck EJ, Narayan R, Nath A, Weiner H, Beh S, Calabresi PA, Steinman L, Major EO, Frohman TC, Frohman EM.

J Neurol. 2017 Apr;264(4):817-828. doi: 10.1007/s00415-016-8293-y. Epub 2016 Oct 12. No abstract available.

PMID:
27734166
49.

INTENSITY INHOMOGENEITY CORRECTION OF MACULAR OCT USING N3 AND RETINAL FLATSPACE.

Lang A, Carass A, Jedynak BM, Solomon SD, Calabresi PA, Prince JL.

Proc IEEE Int Symp Biomed Imaging. 2016 Apr;2016:197-200. Epub 2016 Jun 16.

50.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Kantor D, Sotirchos ES, Calabresi PA.

Neurology. 2016 Sep 27;87(13):1424. doi: 10.1212/01.wnl.0000502811.31151.c9. No abstract available.

PMID:
27672169

Supplemental Content

Loading ...
Support Center